Abel, A, Kimberly, IR, Robert, AV (2006) Incidence and clinical significance of elevated macroprolactin levels in patients with hyperprolactinemia. Endocrine Practice, 12: 275–80.
Bargiota, SI, Bonotis, KS, Messinis, IE, et al (2013) The effects of antipsychotics on prolactin levels and women's menstruation. Schizophrenia Research and Treatment, .
Brugnoli, R, Novick, D, Maria Haro, J, et al (2012) Risk factors for suicide behaviors in the observational schizophrenia outpatient health outcomes (SOHO) study. BMC Psychiatry, 12: 83.
Busche, C, Yeomans, D, Floyd, T, et al (2008) Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics. Journal of Psychopharmacology, 22: 56–62.
Byerly, M, Suppes, T, Tran, QV, et al (2007) Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. Journal of Clinical Psychopharmacology, 27: 639–61.
Byerly, MJ, Marcus, RN, Tran, QV, et al (2009) Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. Schizophrenia Research, 107: 218–22.
Canadian Society of Clinical Chemists (1992) Canadian Society of Clinical Chemists position paper: standardization of selected polypeptide hormone measurements. Clinical Biochemistry, 25: 415–24.
Chang, SC, Chen, C-H, Lu, M-L (2008) Cabergoline-induced psychotic exacerbation in schizophrenic patients. General Hospital Psychiatry, 30: 378–80.
Coker, F, Taylor, D (2010) Antidepressant-induced hyperprolactinaemia incidence, mechanisms and management. CNS Drugs, 24: 563–74.
Corenblum, B, Pairaudeau, N, Shewchuk, AB (1976) Prolactin hypersecretion and short luteal phase defects. Obstetrics and Gynecology, 47: 486–8.
David, SR, Taylor, CC, Kinon, BJ, et al (2000) The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clinical Therapeutics, 22: 1085–96.
Dekkers, OM, Ehrenstein, V, Bengtsen, M, et al (2015) Breast cancer risk in hyperprolactinemia patients: a population-based cohort study and meta-analysis of the literature. European Journal of Endocrinology, 173: 269–73.
De Rivera, JL, Lal, S, Ettigi, P, et al (1976) Effect of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups. Clinical Endocrinology, 5: 273–85.
Di Somma, C, Colao, A, Di Sarno, A, et al (1998) Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. Journal of Clinical Endocrinology and Metabolism, 83: 807–13.
Fell, MJ, Neill, JC, Marshall, KM (2004) Effects of the classical antipsychotic haloperidol and atypical antipsychotic risperidone on weight gain, the oestrous cycle and uterine weight in female rats. European Neuropsychopharmacology, 14: 385–92.
Greenspan, SL, Neer, RM, Ridgway, EC, et al (1986) Osteoporosis in men with hypoprolactinemic hypogonadism. Annals of Internal Medicine, 104: 777–82.
Haddad, PM, Wieck, A (2004) Antipsychotic-induced hyperprolactinaemia mechanisms, clinical features and management. Drugs, 64: 2291–314.
Holt, RIG, Peveler, RC (2011) Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management. Clinical Endocrinology, 74: 141–7.
Inder, WJ, Castle, D (2011) Antipsychotic-induced hyperprolactinaemia. Australian and New Zealand Journal of Psychiatry, 45: 830–7.
Kavanagh-Wright, L, Smith, TP, Gibney, J, et al (2009) Characterization of macroprolactin and assessment of markers of autoimmunity in macroprolactinaemic patients. Clinical Endocrinology, 70: 599–605.
Kelly, DL, Wehring, HJ, Earl, AK, et al (2013) Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin). BMC Psychiatry, 13: 214.
Kleinberg, DL, Noel, GL, Frantz, AG (1977) Galactorrhea: a study of 235 cases, including 48 with pituitary tumors. New England Journal of Medicine, 296: 589–600.
Klibanski, , Neer, RM, Beitins, IZ, et al (1980) Decreased bone density in hyperprolactinemic women. New England Journal of Medicine, 303: 1511–4.
Kotorki, P, Pelka, P, Leotsakou, C, et al (2010) Reversal of symptomatic antipsychotic-induced hyperprolactinemia with addition of aripiprazole. Annals of General Psychiatry, 9 (suppl 1): S164.
La Torre, D, Alberto, F (2007) Pharmacological causes of hyperprolactinemia. Therapeutics and Clinical Risk Management, 3: 929–51.
Melmed, S, Casanueva, FF, Hoffman, AR, et al (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 96: 273–88.
Molitch, ME (2008) Drugs and prolactin. Pituitary, 11: 209–18.
National Institute for Health and Care Excellence (2014) Psychosis and Schizophrenia in Adults: Prevention and Management
Perkins, DO (2004) Antipsychotic induced hyperprolactinemia: pathophysiology and clinical consequences. Advanced Studies in Medicine, 4(10F): S982–6.
Sánchez-Eixerés, MR, Mauri, M, Alfayate, R, et al (2001) Prevalence of macroprolactin detected by Elecsys 2010. Hormone Research, 56: 87–92.
Schlechte, J, Walkner, L, Kathol, M (1992) A longitudinal analysis of premenopausal bone loss in healthy women and women with hyperprolactinemia. Journal of Clinical Endocrinology and Metabolism, 75: 698–703.
Schlechte, JA (2003) Prolactinoma. New England Journal of Medicine, 349: 2035–41.
Segal, S, Yaffe, H, Laufer, N, et al (1979) Male hyperprolactinemia: effects on fertility. Fertility and Sterility, 32: 556–61.
Shim, JC, Shin, JG, Kelly, DL, et al (2007) Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. American Journal of Psychiatry, 164: 1404–10.
Sobrinho, LG (1998) Emotional aspects of hyperprolactinemia. Psychotherapy and Psychosomatics, 67: 133–9.
Sonino, N, Tomba, E, Fava, GA (2007) Psychosocial approach to endocrine disease. Advances in Psychosomatic Medicine, 28: 21–33.
Taylor, D, Paton, C, Kapur, S (2015) The Maudsley Prescribing Guidelines in Psychiatry (12th edn). Wiley-Blackwell.
Tworoger, SS, Eliassen, AH, Sluss, P, et al (2007) A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. Journal of Clinical Oncology, 25: 1482–8.
Tworoger, SS, Eliassen, AH, Zhang, X, et al (2013) A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development. Cancer Research, 73: 4810–9.
Tyson, JE, Hwang, P, Guyda, H, et al (1972) Studies of prolactin secretion in human pregnancy. American Journal of Obstetrics & Gynecology, 113(1): 14–20.
Walters, J, Jones, I (2008) Clinical questions and uncertainty: prolactin measurement in patients with schizophrenia and bipolar disorder. Journal of Psychopharmacology, 22 (suppl 2): 82–9.
Wass, J, Shalet, S, Gale, E, et al (2011) Oxford Textbook of Endocrinology and Diabetes (2nd edn). Oxford University Press.